EPYSQLI® (eculizumab-aagh) is now available to patients living with difficult-to-treat rare diseases like paroxysmal ...

One benefit of your nursing degree is the ability to work in numerous settings. You have the opportunity to specialize in ...

Q4 2024 Earnings Call Transcript March 25, 2025 X4 Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.2 EPS, expectations were $-0.17. Operator: Greetings, and welcome to the ...

Jocelyn and Kristofer Carella-Erickson on their wedding day (left), Jocelyn with her Bambi Squishmallow ...

BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today reported financial results ...

About WHIM Syndrome WHIM syndrome is a rare, combined primary immunodeficiency and chronic neutropenic disorder caused by CXCR4 receptor dysfunction that results in impaired mobilization of white ...

The discovery of a new preclinical compound with strong antifungal activity against multidrug-resistant pathogens is described in Nature.The drug, named mandimycin, is a member of a known family ...

Background: Acute leukemia is an aggressive malignancy with high morbidity and mortality, and chemotherapy is the primary treatment modality. However, chemotherapy often induces neutropenia ...

Department of Drug Chemistry and Technologies Laboratory Affiliated with the Institute Pasteur Italy − Cenci Bolognetti Foundation, Sapienza University of Rome, Rome 00185, Italy ...